- Home
- PRTA vs GERN Comparison
PRTA vs GERN Comparison
Compare PRTA & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- GERN
- Stock Information
- Founded
- PRTA 2012
- GERN 1990
- Country
- PRTA Ireland
- GERN United States
- Employees
- PRTA N/A
- GERN N/A
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- PRTA Health Care
- GERN Health Care
- Exchange
- PRTA Nasdaq
- GERN Nasdaq
- Market Cap
- PRTA 809.8M
- GERN 840.7M
- IPO Year
- PRTA N/A
- GERN 1996
- Fundamental
- Price
- PRTA $9.70
- GERN $1.42
- Analyst Decision
- PRTA Buy
- GERN Buy
- Analyst Count
- PRTA 9
- GERN 11
- Target Price
- PRTA $54.57
- GERN $5.80
- AVG Volume (30 Days)
- PRTA 605.6K
- GERN 13.7M
- Earning Date
- PRTA 05-07-2025
- GERN 05-07-2025
- Dividend Yield
- PRTA N/A
- GERN N/A
- EPS Growth
- PRTA N/A
- GERN N/A
- EPS
- PRTA N/A
- GERN N/A
- Revenue
- PRTA $135,157,000.00
- GERN $76,994,000.00
- Revenue This Year
- PRTA N/A
- GERN $208.83
- Revenue Next Year
- PRTA $131.71
- GERN $57.49
- P/E Ratio
- PRTA N/A
- GERN N/A
- Revenue Growth
- PRTA 47.92
- GERN 32386.92
- 52 Week Low
- PRTA $9.00
- GERN $1.17
- 52 Week High
- PRTA $25.42
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- PRTA 34.03
- GERN 44.54
- Support Level
- PRTA $9.00
- GERN $1.17
- Resistance Level
- PRTA $10.07
- GERN $1.47
- Average True Range (ATR)
- PRTA 0.74
- GERN 0.12
- MACD
- PRTA 0.07
- GERN 0.04
- Stochastic Oscillator
- PRTA 28.00
- GERN 83.33
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.